[New Report] Induced Pluripotent Stem Cells Market is estimated to be US$ 3.5 billion by 2032; Growing Prevalence of Diseases and Demand for Therapies to Foster Industrial Growth - By PMI
June 28, 2023 11:05 ET
|
PMI
Covina, June 28, 2023 (GLOBE NEWSWIRE) -- “According to the latest research study, the demand of “Induced Pluripotent Stem Cells Market accounted for US$ 1.8 billion in 2022 and is estimated to be...
Peptide Synthesis Market is estimated to be US$ 10.8 billion by 2032 with a CAGR of 8.2% over the forecast period (2022-2032) - By PMI
January 05, 2023 08:45 ET
|
PMI
Covina, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Peptide Synthesis and its applications are increasing due to development in bioengineering and biotechnology sector and also used for various research...
F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration
January 05, 2022 08:00 ET
|
F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
Telix and Merck to Commence Pan-Cancer Clinical Combination Studies
August 17, 2021 21:03 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that it has entered into a pan-cancer clinical collaboration...
Telix and Merck KGaA, Darmstadt, Germany, to Commence Pan-Cancer Clinical Combination Studies
August 17, 2021 21:02 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that it has entered into a pan-cancer clinical collaboration...
Global Blood Cell Separation Market – Rising incidence of cancer is encouraging further research in the field, Advances in computer techniques etc. driving market growth - by PMI
January 12, 2021 23:05 ET
|
PMI
Covina, CA, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The market is driven by the increasing use of cell separation in cancer research. In addition, the rising focus on personalized medicine is anticipated...
Global Bio safety Testing Market is Estimated to be US$ 10.5 Billion by 2029 with a CAGR of 13.1% during the forecast Period - PMI
June 09, 2020 10:35 ET
|
PMI
Covina, CA, June 09, 2020 (GLOBE NEWSWIRE) -- The global bio safety testing market accounted for US$ 3.1 billion in 2019 and is estimated to be US$ 10.5 billion by 2029 and is anticipated to...
Vaccinex, Inc. to Present at the Virtual Investor Fireside Chat Series
June 09, 2020 08:00 ET
|
Vaccinex, Inc.
Live video moderated discussion with President and CEO, Maurice Zauderer, Ph.D., on Tuesday, June 16, at 10:00 AM ET, immediately followed by an interactive Q&A session ROCHESTER, N.Y., June 09,...
Vaccinex to Present Updated Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting
May 13, 2020 17:02 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., May 13, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Updated Interim Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer Presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting
April 27, 2020 07:45 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., April 27, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and...